BRNS
Barinthus Biotherapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$0.76
+5.50%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$31.00M
MomentumView details →
1D Return
+5.50%
YTD Return
+8.56%
RSI (14)
63.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$31.00M
RSI (14)
63.6
MomentumView details →
1D Return
+5.50%
YTD Return
+8.56%
SummaryUpdated Jun 1, 2026
Barinthus Biotherapeutics plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Harwell, United Kingdom. Originally known as Vaccitech plc, the company rebranded to Barinthus Biotherapeutics in November 2023. The company went public in April 2021 and focuses on developing novel T cell immunotherapeutics designed to guide the immune system in treating chronic infectious diseases, autoimmune conditions, and cancer.
Similar companies
Latest newsMore news →
Barinthus Biotherapeutics plc transferred its listing from NASDAQ to another exchange, as disclosed in an 8-K filing on August 24, 2026.11d agoBarinthus Biotherapeutics plc completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease.30d ago